Jinhua Xu Selected Research

baohuoside I

1/2020	Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
1/2015	Icariside II inhibits cell proliferation and induces cell cycle arrest through the ROS-p38-p53 signaling pathway in A375 human melanoma cells.
8/2013	Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.
1/2013	Icariside II induces apoptosis of melanoma cells through the downregulation of survival pathways.
9/2012	Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jinhua Xu Research Topics

Disease

17	Neoplasms (Cancer) 01/2022 - 12/2005
17	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2013
14	Melanoma (Melanoma, Malignant) 01/2022 - 09/2012
11	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 06/2011
6	Vitiligo 01/2022 - 12/2018
5	Inflammation (Inflammations) 01/2022 - 12/2011
5	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2015
5	Infections 12/2021 - 06/2017
5	Breast Neoplasms (Breast Cancer) 01/2019 - 09/2008
3	Chronic Urticaria 01/2022 - 01/2015
3	Triple Negative Breast Neoplasms 01/2022 - 01/2015
3	Fibrosis (Cirrhosis) 04/2021 - 04/2016
3	Atopic Dermatitis (Atopic Eczema) 11/2019 - 12/2011
2	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 02/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2021
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 02/2019
2	Dermatitis 10/2021 - 07/2021
2	Skin Diseases (Skin Disease) 09/2021 - 12/2017
2	Disease Resistance 01/2021 - 01/2020
2	Colonic Neoplasms (Colon Cancer) 01/2020 - 03/2017
2	Asthma (Bronchial Asthma) 12/2019 - 12/2011
2	Allergic Rhinitis 12/2019 - 12/2011
2	Psoriatic Arthritis 01/2019 - 03/2017
2	Reperfusion Injury 01/2018 - 02/2015
2	Wounds and Injuries (Trauma) 01/2018 - 01/2015
2	Eczema 12/2017 - 11/2016
2	Stevens-Johnson Syndrome (Lyell's Syndrome) 08/2017 - 10/2009
2	Elastosis perforans serpiginosa 07/2016 - 03/2015
2	Porokeratosis (Palmoplantar Porokeratosis) 01/2016 - 07/2015
2	Alopecia (Baldness) 01/2016 - 01/2015
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2014 - 08/2013
2	Retinoblastoma (Glioblastoma, Retinal) 11/2009 - 02/2009
2	Syphilis 07/2007 - 08/2005
1	Disease Progression 01/2022
1	Animal Diseases 11/2021

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 10/2009
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2011
6	CytokinesIBA 01/2022 - 04/2016
5	baohuoside IIBA 01/2020 - 09/2012
4	Long Noncoding RNAIBA 01/2022 - 01/2020
4	Biological ProductsIBA 01/2022 - 06/2010
4	Messenger RNA (mRNA)IBA 08/2021 - 06/2010
4	CateninsIBA 11/2020 - 01/2015
3	ChemokinesIBA 01/2022 - 10/2013
3	AutoantibodiesIBA 01/2022 - 11/2016
3	AntioxidantsIBA 11/2020 - 01/2018
3	EnzymesIBA 11/2020 - 08/2017
3	Small Interfering RNA (siRNA)IBA 08/2017 - 01/2015
3	DNA (Deoxyribonucleic Acid)IBA 09/2013 - 06/2011
2	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2021
2	Immunoglobulin G (IgG)IBA 01/2022 - 04/2021
2	SalicylatesIBA 01/2022 - 05/2017
2	Circular RNAIBA 01/2022 - 01/2021
2	InterleukinsIBA 01/2022 - 04/2021
2	spesolimabIBA 12/2021 - 01/2021
2	Imiquimod (Aldara)FDA LinkGeneric 10/2021 - 01/2021
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 09/2021 - 03/2015
2	Interleukin-6 (Interleukin 6)IBA 04/2021 - 01/2019
2	Azithromycin (Zithromax)FDA LinkGeneric 04/2021 - 07/2007
2	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2021 - 01/2013
2	CreatinineIBA 04/2021 - 10/2015
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 10/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2020
2	AntibodiesIBA 12/2020 - 01/2015
2	Therapeutic UsesIBA 12/2020 - 11/2019
2	NucleotidesIBA 01/2020 - 01/2014
2	Melanins (Melanin)IBA 12/2019 - 11/2016
2	CollagenIBA 02/2019 - 01/2018
2	SurvivinIBA 07/2018 - 05/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 09/2012
2	Interleukin-8 (Interleukin 8)IBA 12/2017 - 09/2012
2	MicroRNAs (MicroRNA)IBA 02/2017 - 01/2017
2	Penicillamine (Cuprimine)FDA Link 07/2016 - 03/2015
2	Mevalonic Acid (Mevalonate)IBA 01/2016 - 07/2015
2	HLA-B Antigens (HLA-B)IBA 01/2016 - 08/2014
2	Transcription Factors (Transcription Factor)IBA 01/2013 - 04/2010
2	epimedii flavoneIBA 01/2013 - 09/2012
2	MethyltransferasesIBA 01/2013 - 06/2011
2	Penicillins (Penicillin)FDA Link 07/2007 - 08/2005
1	AutoantigensIBA 01/2022
1	LDL Receptors (LDL Receptor)IBA 01/2022
1	anti-thyroid autoantibodiesIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Acitretin FDA Link 01/2022
1	Omalizumab (Xolair)FDA Link 01/2022
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	ZincIBA 01/2022
1	IronIBA 01/2022
1	ERRalpha Estrogen-Related ReceptorIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	Immunoglobulin E (IgE)IBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2021
1	Sulfamethoxazole FDA LinkGeneric 11/2021

Therapy/Procedure

10	Therapeutics 03/2021 - 10/2009
4	Immunotherapy 01/2022 - 12/2019
2	Photochemotherapy (Photodynamic Therapy) 09/2021 - 03/2021